Product Information
CANDESARTAN CILEXETIL 32 MG TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.5189 per EA under NDC 00378323293. Its NADAC has been published 343 times since Mar 11, 2020.
FDA first approved this application on May 3, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
32 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378323293
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CANDESARTAN CILEXETILApproval Type
Generic (ANDA)
FDA Application
ANDA078702FDA Approved
5/3/2013
TE Code
AB
On Market Since
1/6/2020
Pharmacological Classes
Price Statistics
The NADAC for CANDESARTAN CILEXETIL 32 MG TB has been published 343 times since Mar 11, 2020, and over the history we have for it it has declined 64.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5189 per EA |
|---|---|
| All-time high | $1.4516 (May 13, 2020) |
| All-time low | $0.5107 (Aug 19, 2026) |
| 52-week high | $0.6049 |
| 52-week low | $0.5107 |
| Median price | $0.9606 |
| Average price | $0.9387 |
| Largest weekly change | -34.5% (Nov 20, 2024) |
| Weeks tracked | 343 |
| Tracking since | Mar 11, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
candesartan cilexetil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CANDESARTAN CILEXETIL 32 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN CILEXETIL 32 MG TB, manufactured by Mylan Pharmaceuticals Inc., is $0.5189 per EA (NDC 00378323293), effective Sep 30, 2026.
How has the price of CANDESARTAN CILEXETIL 32 MG TB changed over time?
Over the history we have for it, the NADAC for CANDESARTAN CILEXETIL 32 MG TB has declined 64.0%. It has been tracked across 343 weekly CMS publications since Mar 11, 2020.
What are the highest and lowest recorded NADAC prices for CANDESARTAN CILEXETIL 32 MG TB?
Since Mar 11, 2020, the NADAC for CANDESARTAN CILEXETIL 32 MG TB has ranged from a low of $0.5107 (Aug 19, 2026) to a high of $1.4516 (May 13, 2020), with a median of $0.9606 per EA.
Are there cheaper alternatives to CANDESARTAN CILEXETIL 32 MG TB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CANDESARTAN CILEXETIL 32 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures CANDESARTAN CILEXETIL 32 MG TB?
CANDESARTAN CILEXETIL 32 MG TB (NDC 00378323293) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.